Teneligliptin
Lua error in Module:Infobox at line 314: malformed pattern (missing ']'). Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]
Creation
It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.[2]
Licensing and use
Japan/Korea
It is approved for use in Japan, Korea and India. [3]
Pharmacology
Teneligliptin has unique J shaped or anchor locked domain structure because of which it has more potent inhibition of DPP 4 enzyme as compared to Sitagliptin and Vildagliptin.[citation needed]
Teneligliptin significantly controls glycemic parameters[clarification needed] with safety. No dose adjustment is required in renally impaired patients.[4]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006054.html
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Biochemical and Biophysical Research Communications, 2013, 434(2), 191-196
- Pages with reference errors
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Articles with unsourced statements from November 2015
- Wikipedia articles needing clarification from November 2015
- Dipeptidyl peptidase-4 inhibitors
- Pyrazoles
- Piperidines
- Gastrointestinal system drug stubs